This drug could offer a potential new treatment approach for patients with treatment-refractory advanced squamous-cell carcinoma. Funding: Ono Pharmaceutical, Bristol-Myers Squibb.
Book Title: Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial
Author:
Published on 2017 by
ISBN: /
Total Page:
Book Category:
Book is About: Carcinoma treatment
Download Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial eBook
Background: Nivolumab is a human monoclonal IgG4 antibody that inhibits programmed cell death protein 1 (PD-1) expressed on activated T cells. We investigated the safety and activity of nivolumab in patients with treatment-refractory oesophageal cancer. Methods: We did an open-label, single-arm, multicentre phase 2 study. Eligible patients had advanced squamous-cell carcinoma, adenosquamous-cell carcinoma, or adenocarcinoma of the oesophagus refractory or intolerant to fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy. Patients were treated with 3 mg/kg nivolumab given intravenously once every 2 weeks in 6-week cycles. The primary endpoint was centrally assessed objective response (the proportion of patients whose best response was complete or partial response), according to the Response Evaluation Criteria In Solid Tumors, version 1.1. Adverse events and treatment-related adverse events (defined as events for which a causal relation to nivolumab could not be ruled out) were monitored throughout the study. The safety analysis was done in patients who received at least one dose of nivolumab, and drug activity was assessed in patients who received at least one dose of nivolumab and had at least one central assessment of tumour response. This study is registered with clinicaltrials.jp, number ONO-4538-07/JapicCTI-No.142422. Follow-up of patients is ongoing. Findings: Between Feb 25 and Nov 14, 2014, 65 patients were enrolled, all with squamous-cell carcinoma. 64 patients were assessable for the primary endpoint as one patient was excluded due to having multiple primary cancers; all patients were assessable for safety. Median follow-up was 10·8 months (IQR 4·9–14·3). 11 (17%, 95% CI 10–28) of 64 patients had a centrally assessed objective response. Of the 65 patients assessed for adverse events, the most common grade 3 or 4 events were grade 4 dyspnoea and hyponatraemia (one [2%) patient each), grade 3 lung infection (five [8%] patients), grade 3 decreased appetite (two [3%] patients), grade 3 increased blood creatinine phosphokinase (two [3%] patients), and grade 3 dehydration (two [3%] patients). Serious adverse events that occurred during the study were lung infection (four [6%] patients), dehydration (two [3%]), interstitial lung disease (two [3%]), and hyponatraemia, dyspnoea, fatigue, abnormal hepatic function, diarrhoea, bile duct stenosis, gastroenteritis, pneumonia, oedema, and back pain (one [2%] patient each). There were no treatment-related deaths. Interpretation: Nivolumab showed promising activity with a manageable safety profile. This drug could offer a potential new treatment approach for patients with treatment-refractory advanced squamous-cell carcinoma. Funding: Ono Pharmaceutical, Bristol-Myers Squibb.
Our website offers free Carcinoma treatment Ebooks to download. Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial is the one of great book to have from us, a free ebooks portal, the best free ebooks download library. You can find and download free ebooks in categories. No registration is required to download free e-books. We have huge collection of Carcinoma treatment and ebooks. Each downloadable ebook has a short review with a description. You can find over thousand of ebooks that are free to download. Get ton of books with us, the open directory for free ebooks and download links, the best place to read ebooks and search free download ebooks.Carcinoma treatment ebooks free
download Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial ebook as PDF, EPUB, MOBI, AZW and AZW3, FB2, DJVU, LIT, RFT, IBA, LRS, LRF, and LRX.
download ebooks
There are so many ebooks about Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial that are available to have. Thinking of having Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial ebook? You are in the right place. Get the ebook Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial by: .
Book Details:
- Book was ranked at 32 by Google Books for Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial
- Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial published by since 2017 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
- Reading Mode in Text Status is false and Reading Mode in Image Status is false
- The book has " Pages" is Printed at BOOK under Category
- Rated by Raters and have average rate at ""
- eBook written in en
- Book Preview Address: http://books.google.com/books?id=MKwAvgEACAAJ&dq=Carcinoma+treatment&hl=&cd=311&source=gbs_api
Book Preview
The Button is not working? Try The Alternative links for "Nivolumab Treatment for Oesophageal Squamous-cell Carcinoma: an Open-label, Multicentre, Phase 2 Trial by: ":
- Server 2: SECURE LINK